China leads in adopting recombinant antibodies


Min Read

In this blog:

  • The recombinant antibody market is exciting and fast-past
  • Chinese institutions are carrying out the most research using recombinant antibodies
  • Which means China is reaping the benefits of these products

The recombinant antibody market is an exciting and fast-past market in which there has been year-on-year growth and where we see a lot of change. 

Earlier this year we added a feature to our search engine at CiteAb that allowed researchers to filter our antibody search results to show recombinant antibodies. In a post I wrote at that time I explained why researchers might want to use these products, looking at the benefits they offer. 

Today I am going to take another look at this market and explore the geographical differences that exist – which countries and regions are using these products the most, which are seeing the fastest growth in their use, and which research institutions are the most active?   

To carry out the analysis that I am sharing with you today I looked at our data for over 175,000 antibodies from over 41 different suppliers. These products have hundreds of thousands of citations which give us a really powerful insight into this market.

Globally, the two countries using the most recombinant antibodies are the USA and China, but this doesn’t necessarily mean that these are the fastest-growing markets that suppliers might wish to focus on. 

In fact, while the USA does show a positive use trajectory, it is still one of the slowest growing markets that I am going to discuss today. Recombinant antibodies made up 3.55 per cent of all antibodies used in research in the USA in 2010, and by 2019 this had increased to 13.79 per cent. A reasonable increase, but one which pales when compared to what we see in other markets. 

In comparison, China has a very strong growth rate in the use of these products. Recombinant antibodies made up 3.6 per cent of all antibodies used in research in China in 2010, and by 2019 this had increased to 26.9 per cent. 

Japan has also seen a fast increase in the use of recombinant antibodies – from 2.93 per cent of all antibodies used in 2010 to 15.54 per cent by 2019. And Europe’s use has increased over the same time period from 2.9 per cent to 10.66 per cent. 

From my analysis today I can also pinpoint which research institutions are doing the most research with recombinant antibodies. 

In 2019, over a hundred different institutions in China used recombinant antibodies, with Shanghai Jiao Tong University and Zhejiang University at the top of the leader board. 

There has been immense growth in research in the life sciences in China over recent years, and we see evidence of this when we look at the growth of many different sectors of the life science market demonstrated by our data. This growth is being supported in the country by the creation of new laboratories, and these are often quick to adopt recombinants – maybe they haven’t already got existing preferences for monoclonal or polyclonal antibodies.  

Obviously, increased use of recombinant antibodies will also come with increased access to the benefits they offer for reproducibility, validation, achieving sensitivity and the scaling of experiments – China will be benefiting from this as a result of its extensive use of these products. 

Today I am giving away for free our data illustrating the top ten institutions using recombinant antibodies in China – you can get your copy sent direct to your inbox by signing up using the form below. 

If you have any questions about our insights on recombinant antibody use, or any other part of the global antibody market, then I would be happy to hear from you. Do get in touch and I can help you out. 

– Rhys and the CiteAb team 

Sign up for data

Something seems to have gone wrong while loading the form.
Drop us a message and we can send you the data directly.

About the author

Join thousands of people who already enjoy the CiteAb newsletter

To keep up to date with the latest developments to our search engine, news from our life science market data analysis and improvements to our citation provision.